Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis.

摘要: Repeated bouts of acute and chronic lung infections are responsible for progressive pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to respiratory failure death. Pseudomonas aeruginosa is the archetypical CF pathogen, causes infection 70% individuals, associated an accelerated clinical decline. The management P. has been revolutionized development widespread use inhaled antibiotics. Aerosol delivery antimicrobial compounds enables extremely high concentrations antibiotics be reached directly at site potentially overcoming adaptive resistance avoiding potential cumulative systemic toxicities. Tobramycin inhalation powder (TIP) represents first dry (DPI) antibiotic available CF. DPIs notable a markedly reduced time administration, ease portability, increased compliance. TIP developed as therapeutic alternative tobramycin solution (TIS), standard care past 20 years within Relative TIS 300 mg nebulized twice daily on-and-off cycles 28 days duration, 112 via T-326 inhaler administered on same schedule marked savings, patient satisfaction, comparable end points. innovative treatment strategy those holds promise compliance thus improved outcomes.